Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Sponsor
Asan Medical Center
Study ID
NCT00378066
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab, Capecitabine, Oxaliplatin

Study Details

The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.

Key Dates

First listed
Sep 19, 2006
Start date
Aug 31, 2006
Status verified
Jan 2013
Primary completion
Aug 31, 2006
Completion
Oct 31, 2008

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Active Comparator: Bevacizumab
    Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment

Primary Outcome Measure

time to progression [ Time Frame: 6 months ]

Related Studies